1295570-08-9

Basic information

• Product Name: 4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)aniline hydrochloride
• Synonyms: 4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)aniline hydrochloride
• CAS NO: 1295570-08-9
• Molecular Weight: 292.732
• Mol File: 1295570-08-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)aniline hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)aniline hydrochloride(1295570-08-9)
• EPA Substance Registry System: 4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)aniline hydrochloride(1295570-08-9)

Safety Data

• Hazardous Substances Data: 1295570-08-9(Hazardous Substances Data)

Upstream product

• 1295570-09-0 7-[4-nitro-3-(trifluoromethyl) phenyl]-7-azabicyclo[2.2.1]heptane hydrochloride 
• 1272319-79-5 trans-4-aminocyclohexylmethanesulfonate trifluoroacetic acid salt 
• 27514-07-4 7-azabicyclo[2.2.1]heptane hydrochloride 
• 177545-89-0 (1r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl methanesulfonate 
• 111300-06-2 trans-tert-butyl 4-hydroxycyclohexylcarbamate 
• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 1221573-19-8 7-[4-nitro-3-(trifluoromethyl) phenyl]-7-azabicyclo[2.2.1]heptane 

Relevant articles and documents

PROCESS FOR PREPARING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention relates to processes for preparing solid state forms of N-(4-(7-azabicyclo[2.2. 1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, including Compound 1 Form A, Compound 1 Form A- HCl, Compound 1 Form B, and Compound 1 Form B-HCl, any combination of these forms, pharmaceutical compositions thereof, and methods of treatment therewith.

SOLID FORMS OF N-(4-(7-AZABICYCLO[2.2.1]HEPTAN-7-YL)-2-TRIFLUOROMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE

The present invention relates to substantially crystalline and solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide (Form A-HCl, Form B, Form B-HCl, or any combination of these forms), pharmaceutical compositions thereof, and methods of treatment therewith.